摘要
目的观察病理确诊的晚期非小细胞肺癌(NSCLC)患者在一线化疗控制后行紫杉醇脂质体单药维持治疗的疗效。方法晚期NSCLC患者60例,一线化疗方案治疗后疾病稳定,随机均分为两组。治疗组给予紫杉醇脂质体每天135mg/m^2,21d为1个周期,行4或6个周期治疗,治疗完成后评价疗效、生活质量及不良反应;对照组不用维持治疗。结果治疗组客观缓解率(ORR)和疾病控制率(DCR)均高于对照组(36%vs.13%和83%vs.53%)(P<0.05)。治疗组中位疾病无进展生存期(PFS)高于对照组(4.5个月vs.2.9个月)(P<0.05)。治疗组患者中,既往未接受过紫杉类化疗的ORR、DCR及中位PFS均高于接受过紫杉类化疗者,但差异无统计学意义(P>0.05)。治疗组主要不良反应为骨髓抑制、神经毒性和肌肉毒性等,均可耐受。结论紫杉醇脂质体作为NSCLC患者的维持治疗临床疗效明显,不良反应可耐受。
Objective To observe the efficacy paclitaxel liposome as a maintenance treatment after first-line treatment in the patients with advanced non-small cell lung cancer（NSCLC） diagnosed pathologically. Methods Sixty advanced NSCLC patients with stable disease after first-line therapy were equally divided into two groups of A and B. Group A was treated with paclitaxel liposomeasa 135 mg/m^2 , daily for 21 days as a cycle. The efficacy, quality of life and adverse effects were evaluated after 4 or 6 cycles. Group B was not given maintenance treatment as the control. Results The objective response rate（ORR） and disease control rates （DCR） in group A were higher than those in group B（36% vs. 13% and 83% vs. 53%） （P〈0. 05）. The disease progression-free surial（PFS） in group A was higher than that in group B（4. 5 months vs. 2. 9 months） （P〈0. 05）. The ORR,DCR and median PFS were all higher in the patients treated with paelitaxel chemotherapy before than those in patients without （P〉0. 05）. The most common adverse effects in group A were bone marrow suppression, neurotoxicity and muscle toxicity, which were all tolerable. Conclusion As the maintenance therapy, paclitaxel liposome has obvious clinical efficacy with tolerable adverse effects in the patients with advanced NSCLC.
出处
《江苏医药》
CAS
2016年第15期1677-1680,共4页
Jiangsu Medical Journal
关键词
紫杉醇脂质体
非小细胞肺癌
Paclitaxel liposome
Non-small cell lung cancer
